SEC Form 4Coverage since Jun 22, 2026
$OKUR insider trading
Over the last 12 months, OnKure Therapeutics insiders reported no purchases and 2 sales totaling $2K across SEC Form 4 filings.
- Bought · 12m
- — 0 events
- Sold · 12m
- $2K 2 events
- Events · 12m
- 2 Form 4 filings, grouped
- Insiders · 12m
- 2 distinct reporters
- 10b5-1 share
- 0% pre-arranged plans
Side
Price · $OKUR · 12Mvia TradingView
Top insiders · 12m
Saccomano Nicholas APresident and CEO1× · $378
Leverone Jason A.Chief Financial Officer1× · $1K
All insider trades
2 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jun 22, 2026 | Saccomano Nicholas APresident and CEO · O·D | ▼ Sale | 86 | $4.4 | $378 | -0.8% | — |
| Jun 22, 2026 | Leverone Jason A.Chief Financial Officer · O | ▼ Sale | 303 | $4.4 | $1K | -1.6% | — |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $OKUR feed.